共 50 条
Are active dwell positions always necessary in the ring/ovoids channel of the cervical applicator in the intracavitary-interstitial brachytherapy of cervical cancer?
被引:0
|作者:
Frohlich, Georgina
[1
,2
]
Vizkeleti, Julia
[1
]
Nguyen, Anhhong Nhung
[1
]
Polgar, Csaba
[1
,3
]
Takacsi-Nagy, Zoltan
[1
,3
]
Major, Tibor
[1
,3
]
机构:
[1] Natl Inst Oncol, Ctr Radiotherapy, Budapest, Hungary
[2] Eotvos Lorand Univ, Dept Biophys, Fac Nat Sci, Budapest, Hungary
[3] Semmelweis Univ, Dept Oncol, Fac Med, Budapest, Hungary
关键词:
cervical cancer;
ring activation;
ring applicator;
Venezia applicator;
interstitial brachytherapy;
GUIDED ADAPTIVE BRACHYTHERAPY;
SOCIETY CONSENSUS GUIDELINES;
LOCALLY ADVANCED-CARCINOMA;
RADIATION-THERAPY;
AMERICAN BRACHYTHERAPY;
MRI;
RADIOTHERAPY;
POINT;
RECOMMENDATIONS;
FEASIBILITY;
D O I:
10.5114/jcb.2023.124399
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Purpose: To compare dosimetric parameters of brachytherapy (BT) treatment plans made with or without active source positions of the ring/ovoid (R/O) applicator in locally advanced cervical cancer patients. Material and methods: Sixty patients with cervical cancer without vaginal involvement were selected for the study, who received intra-cavitary/interstitial BT. For each patient, two plans with and without active source dwell positions in R/O were created, using the same dose-volume constraints. EQD2 total doses from external beam and BT of target volumes and organs at risk (OARs) between the competing plans were compared. Results: There was no significant difference in the dose of high-risk clinical target volume (HR-CTV) and gross tumor volume (GTV) between the plans with inactive vs. active R/O. The mean D98 of intermediate-risk clinical target volume (IR-CTV) was significantly lower with inactive R/O; however, the GEC-ESTRO (EMBRACE II study) and ABS criteria were fulfilled in 96% in both plans. There was no difference in dose homogeneity, but conformity of the plans with inactive R/O was higher. Doses to all OARs were significantly lower in plans without R/O activation. While all the plans without R/O activation fulfilled the recommended dose criteria for OARs, it was less achievable with R/O activation. Conclusions: Inactivation of R/O applicator results in similar dose coverage of the target volumes with lower doses to all OARs, as activation of R/O in cervix cancer patients when HR-CTV does not extend to R/O applicator. The use of active source positions in R/O shows worse performance regarding the fulfilment of the recommended criteria for OARs.
引用
收藏
页码:48 / 56
页数:9
相关论文